Nicardipine Aguettant (Nicardipine Hydrochloride)

Nicardipine Hydrochloride, the active ingredient in Nicardipine Aguettant, is a calcium channel blocker presented as an intravenous solution for infusion use. It is employed to manage hypertension, acute coronary syndromes, angina pectoris, and to achieve controlled hypotension during surgical procedures. GNH USA supplies Nicardipine Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicardipine is a calcium channel blocker used in cardiovascular conditions where vascular tone modulation is required.

Hypertension: provides vasodilation to lower elevated blood pressure. Acute coronary syndrome: improves myocardial perfusion by reducing afterload. Angina pectoris: relieves chest pain through coronary artery dilation. Controlled hypotension during surgery: enables precise blood pressure reduction for operative field management.

Adverse reactions may occur with intravenous nicardipine and are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Tachycardia: increased heart rate, often dose‑related. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: abrupt and marked blood pressure drop. - Myocardial infarction: rare ischemic cardiac event. - Arrhythmia: potentially life‑threatening rhythm disturbances.

Careful assessment and monitoring are required when administering nicardipine intravenously.

Monitor blood pressure: adjust infusion rate to maintain target levels. Use cautiously in hepatic impairment: reduced clearance may increase exposure. Avoid rapid IV bolus: administer as controlled infusion to prevent sudden hypotension. Assess for heart failure: monitor for signs of fluid overload. Store at ambient temperature: keep in original container, protect from moisture and light.

Nicardipine may interact with other agents that affect vascular tone or drug metabolism.

Major Interactions (Avoid): - Concurrent potent vasodilators: risk of excessive hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nicardipine plasma levels. - Nitrates: additive vasodilatory effect leading to severe blood pressure fall.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt compensatory tachycardia. - Diuretics: enhanced antihypertensive effect. - ACE inhibitors or ARBs: additive blood pressure reduction. - NSAIDs: may attenuate antihypertensive response.